Microvascular abnormalities in patients with early systemic sclerosis: Less severe morphological changes than in patients with definite disease

Scandinavian Journal of Rheumatology

Volumn 44, Issue 1, 2015, Pages 48-55

  Camargo, C Z ^a   Sekiyama, J Y ^a   Arismendi, M I ^a   Kayser, C ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; VASODILATOR AGENT; VON WILLEBRAND FACTOR; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD FLOW; BLOOD VESSEL INJURY; CAPILLAROSCOPY; CAPILLARY; COLD; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMAGING; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; MIDDLE AGED; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SKIN BLOOD FLOW; STIMULUS; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; AGED; ANGIOSCOPY; BLOOD; CROSS-SECTIONAL STUDY; FINGER; IMMUNOLOGY; METABOLISM; MICROVASCULATURE; PATHOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX; VASCULARIZATION;

ADULT; AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; ENDOTHELIN-1; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FINGERS; HUMANS; MALE; MICROCIRCULATION; MICROSCOPIC ANGIOSCOPY; MICROVESSELS; MIDDLE AGED; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TRANSFORMING GROWTH FACTOR BETA1; VON WILLEBRAND FACTOR;

EID: 84920830307     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2014.926566     Document Type: Article

References (52)

1. Wigley FM. Clinical practice. Raynaud's phenomenon. N Engl J Med 2002;347:1001-8.
2. LeRoy EC, Medsger TA. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 1992;10:485-8.
3. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
4. Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 2005;44:587-96.
5. Ennis H, Vail A, Wragg E, Taylor A, Moore T, Murray A, et al. A prospective study of systemic sclerosis-related digital ulcers: prevalence, location, and functional impact. Scand J Rheumatol 2013;42:483-6.
6. Maricq HR. Wide-field capillary microscopy. Arthritis Rheum 1981;24:1159-65.
7. Maricq HR, Maize JC. Nailfold capillary abnormalities. Clin Rheum Dis 1982;8:455-78.
8. Kayser C, Sekiyama JY, Próspero LC, Camargo CZ, Andrade LE. Nailfold capillaroscopy abnormalities as predictors of mortality in patients with systemic sclerosis. Clin Exp Rheumatol 2013;31(Suppl 76):103-8.
9. Cutolo M, Grassi W, Matucci Cerinic M. Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum 2003;48:3023-30.
10. Herrick AL, Clark S. Quantifying digital vascular disease in patients with primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1998;57:70-8.
11. Murray AK, Herrick AL, King TA. Laser Doppler imaging: a developing technique for application in the rheumatic diseases. Rheumatology (Oxford) 2004;43:1210-18.
12. Correa MJ, Andrade LE, Kayser C. Comparison of laser Doppler imaging, fingertip lacticemy test, and nailfold capillaroscopy for assessment of digital microcirculation in systemic sclerosis. Arthritis Res Ther 2010;12:R157.
13. Schachna L, Wigley FM. Targeting mediators of vascular injury in scleroderma. Curr Opin Rheumatol 2002;14:686-93.
14. Sticherling M. The role of endothelin in connective tissue diseases. Rheumatology (Oxford) 2006;45(Suppl 3):iii8-10.
15. Kahaleh MB, Osborn I, LeRoy EC. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med 1981;94:482-4.
16. Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008;14:171-232.
17. Denton CP, Abraham DJ. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001;13:505-11.
18. Matucci-Cerinic M, Bellando-Randone S, Lepri G, Bruni C, Guiducci S. Very early versus early disease: the evolving definition of the 'many faces' of systemic sclerosis. Ann Rheum Dis 2013;72:319-21.
19. Bellando-Randone S, Guiducci S, Matucci-Cerinic M. Very early diagnosis of systemic sclerosis. Pol Arch Med Wewn 2012;122(Suppl 1):18-23.
20. LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
21. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
22. Andrade LE, Gabriel Júnior A, Assad RL, Ferrari AJ, Atra E. Panoramic nailfold capillaroscopy: a new reading method and normal range. Semin Arthritis Rheum 1990;20:21-31.
23. Sekiyama JY, Camargo CZ, Andrade LE, Kayser C. Reliability of widefield nailfold capillaroscopy and videocapillaroscopy in the assessment of patients with Raynaud's phenomenon. Arthritis Care Res 2013;65:1853-61.
24. Maricq HR, LeRoy EC. Patterns of finger capillary abnormalities in connective tissue disease by 'wide-field' microscopy. Arthritis Rheum 1973;16:619-28.
25. Lee P, Leung FY, Alderdice C, Armstrong SK. Nailfold capillary microscopy in the connective tissue diseases: a semiquantitative assessment. J Rheumatol 1983;10:930-8.
26. Sulli A, Secchi ME, Pizzorni C, Cutolo M. Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis 2008;67:885-7.
27. Cutolo M, Pizzorni C, Tuccio M, Burroni A, Craviotto C, Basso M, et al. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology (Oxford) 2004;43:719-26.
28. Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011;70:476-81.
29. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008;58:3902-12.
30. Valentini G, Vettori S, Cuomo G, Iudici M, D' Abrosca V, Capocotta D, et al. Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement. Arthritis Res Ther 2012;14:R188.
31. De Angelis R, Grassi W, Cutolo M. A growing need for capillaroscopy in rheumatology. Arthritis Rheum 2009;61:405-10.
32. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737-47.
33. Grassi W, De Angelis R. Capillaroscopy: questions and answers. Clin Rheumatol 2007;26:2009-16.
34. Smith V, Pizzorni C, De Keyser F, Decuman S, Van Praet JT, Deschepper E, et al. Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study. Ann Rheum Dis 2010;69:1092-6.
35. Caramaschi P, Canestrini S, Martinelli N, Volpe A, Pieropan S, Ferrari M, et al. Scleroderma patients nailfold videocapillaroscopic patterns are associated with disease subset and disease severity. Rheumatology (Oxford) 2007;46:1566-9.
36. Smith V, Decuman S, Sulli A, Bonroy C, Piettte Y, Deschepper E, et al. Do worsening scleroderma capillaroscopic patterns predict future severe organ involvement? A pilot study. Ann Rheum Dis 2012;71:1636-9.
37. Ennis H, Moore T, Murray A, Vail A, Herrick AL. Further confirmation that digital ulcers are associated with the severity of abnormality on nailfold capillaroscopy in patients with systemic sclerosis. Rheumatology (Oxford) 2014;53:376-7.
38. Sebastiani M, Manfredi A, Colaci M, D'Amico R, Malagoli V, Giuggioli D, et al. Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum 2009; 61:688-94.
39. Smith V, De Keyser F, Pizzorni C, Van Praet JT, Decuman S, Sulli A, et al. Nailfold capillaroscopy for day-to-day clinical use: construction of a simple scoring modality as a clinical prognostic index for digital trophic lesions. Ann Rheum Dis 2011;70:180-3.
40. Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000;27:155-60.
41. Scheja A, Wildt M, Wuttge DM, Hesselstrand R. Progressive capillary loss over a decade in patients with systemic sclerosis, in particular in patients with early digital ischaemic manifestations. Scand J Rheumatol 2011;40:457-61.
42. Rosato E, Borghese F, Pisarri S, Salsano F. Laser Doppler persfusion imaging is useful in the study of Raynaud's phenomenon and improves the capillaroscopic diagnosis. J Rheumatol 2009;36:2257-63.
43. Rosato E, Molinaro I, Rossi C, Pisarri S, Salsano F. The combination of laser Doppler perfusion imaging and photoplethysmography is useful in the characterization of scleroderma and primary Raynaud's phenomenon. Scand J Rheumatol 2011;40:292-8.
44. Murray AK, Moore TL, Manning JB, Taylor C, Griffiths CE, Herrick AL. Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders. Arthritis Rheum 2009;61:1103-11.
45. Della Rossa A, Cazzato M, d'Ascanio A, Tavoni A, Bencivelli W, Pepe P, et al. Alteration of microcirculation is a hallmark of very early SSc patients: a laser speckle contrast analysis. Clin Exp Rheumatol 2013;31(Suppl 76):109-14.
46. Rabquer BJ, Koch AE. Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep 2012;14:56-63.
47. Sulli A, Soldano S, Pizzorni C, Montagna P, Secchi ME, Villaggio B, et al. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis. J Rheumatol 2009;36:1235-9.
48. Herrick AL, Illingworth K, Blann A, Hay CR, Hollis S, Jayson MI. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996;55:122-7.
49. Brevetti G, De Caterina M, Martone VD, Corrado S, Silvestro A, Spadaro G, et al. Measurement of soluble adhesion molecules in primary Raynaud's phenomenon and in Raynaud's phenomenon secondary to connective tissue diseases. Int J Clin Lab Res 2000;30:75-81.
50. Leppert J, Ringqvist A, Karlberg BE, Ringqvist I. Whole-body cooling increases plasma endothelin-1 levels in women with primary Raynaud's phenomenon. Clin Physiol 1998;18:420-5.
51. Valentini G, Marcoccia A, Cuomo G, Vettori S, Iudici M, Bondanini F, et al. Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers. Arthritis Res Ther 2013;15:R63.
52. Herrick AL, Cutolo M. Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum 2010;62:2595-604.